#276 Understanding the chemistry of NVG-291’s efficacy for Rewiring SCI Recovery with Inventor Dr. Brad Lang

Brad Lang, PhD, is the neuroscientist and biotech inventor of the ISP drug, the basis of the NVG-291 trials which recently showed efficacy. His work has helped pave the way for one of the most promising new treatments for spinal cord injury in decades. Brad shares the story of how his early research led to the discovery of the intracellular sigma peptide (ISP), a molecule with the potential to unlock axon regeneration and repair damaged neural pathways. We explore the science behind ISP, the challenges of moving from lab discovery to human trials, and the role of persistence at big ideas (a mission imprinted on him by the late Dr. Jerry Silver) when the odds—and the nervous system—seem stacked against recovery.  Along the way, Brad reflects on the emotional journey of being a scientist chasing a breakthrough, the worldwide attention on NervGen’s NVG-291, and the hope these advances bring not only to the SCI community but to the future of treatments for conditions once thought untreatable, and the potential reshaping of lives for those living years with SCI.

Resources